Viridian Therapeutics, Inc.
NASDAQ:VRDNBiotechnology
-$0.15 today
- Market cap
- $3.42B
- Beta
- 0.90
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$3.53
Volume 1.49M
Average 2.86M
VRDN Interest Expense
Cost of servicing the company's debt during the period.
Viridian Therapeutics, Inc.NASDAQ: VRDN
Interest Expense · Q2 FY2026 · quarter ended Jun 2026
Interest expense growth accelerates
Q2 FY2026 interest expense of $8.31M rose 1516.1% year over year, ahead of the +539.3% change in trailing-twelve-month interest expense. Sequentially, it rose 139.9% from the prior quarter. Over 3 fiscal years it compounded at +116.7% a year.
Context
- Interest expense amounted to 7.0% of revenue in FY2025, down 1001.6 pp from a year earlier.
- Interest expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +1516.1% holds above the trailing-twelve-month pace of +539.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 4.95M USD
- Year-over-year change
- +62.4%
- 4-year CAGR
- +537.3%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.95M | +62.4% |
| FY2024 | 2024-12-31 | 3.05M | +64.9% |
| FY2023 | 2023-12-31 | 1.85M | +280.0% |
| FY2022 | 2022-12-31 | 486K | +16100.0% |
| FY2021 | 2021-12-31 | 3K | — |
Interest Expense vs competitors
How VRDN compares with its peers on the latest reported figures
- VRDN's LTM Jun 2026 interest expense of $18.94M is the highest of the 4 companies compared; the peer median is $313.51K.
- Its year-over-year change of +539.3% is the highest of 3, against a peer median of -53.5%.
- Interest expense amounts to 26.6% of revenue for VRDN, versus a peer median of 22.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $18.94M | +539.3% | +116.7% | 26.6% | |
| LTM Mar 2026 | $11.63M | -7.1% | +19.0% | 22.3% | |
| LTM Mar 2026 | $313.51K | — | -42.5% | 94.1% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding VRDN) | $313.51K | -53.5% | -11.7% | 22.3% | |
Competitors are the stored peer set for VRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.96M | 1.77M | 314K | 302K | 70.85M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.96M | 1.77M | 314K | 302K | 70.85M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 56.89M | 100.89M | 159.77M | 238.25M | 338.93M |
| Selling, General & Admin | 25.81M | 35.18M | 95M | 61.08M | 95.32M |
| Operating Expenses | 82.69M | 136.08M | 254.76M | 299.34M | 434.24M |
| Depreciation & Amortization | 120K | 255K | 522K | 540K | 460K |
| EBITDA | (79.29M) | (129.13M) | (235.37M) | (266.36M) | (337.19M) |
| EBITDA Margin | -2676.0% | -7287.4% | -74957.0% | -88199.7% | -475.9% |
| Operating Income | (79.73M) | (134.3M) | (254.45M) | (299.04M) | (363.4M) |
| Operating Margin | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| Interest Income | 318K | 4.92M | 18.56M | 32.13M | 27.4M |
| Interest Expense | 3K | 486K | 1.85M | 3.05M | 4.95M |
| Other Income / Expenses | 315K | 4.43M | 16.72M | 29.09M | 20.79M |
| Income Before Tax | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Pre-Tax Margin | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (79.41M) | (129.87M) | (237.73M) | (269.95M) | (342.6M) |
| Net Margin | -2680.2% | -7329.2% | -75711.5% | -89387.1% | -483.6% |
| EPS (Basic) | (6.66) | (3.91) | (5.31) | (3.98) | (3.32) |
| EPS (Diluted) | (6.66) | (3.91) | (5.31) | (3.98) | (3.32) |
| Weighted Avg Shares | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M |
| Weighted Avg Shares (Diluted) | 11.92M | 32.09M | 44.76M | 67.89M | 84.8M |
Viridian Therapeutics, Inc.
NASDAQ:VRDN
Intrinsic Alpha fair value
Locked
Current Price
$30.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.